Report cover image

Bronchodilators Market by Drug Class (Anticholinergic Bronchodilators, Beta-Adrenergic Bronchodilators, Xanthine Derivative), Route of Administration (Injectable, Nasal, Oral), Disease, End-users - Global Forecast 2023-2030

Publisher 360iResearch
Published Oct 05, 2023
Length 184 Pages
SKU # IRE18313504

Description

Bronchodilators Market by Drug Class (Anticholinergic Bronchodilators, Beta-Adrenergic Bronchodilators, Xanthine Derivative), Route of Administration (Injectable, Nasal, Oral), Disease, End-users - Global Forecast 2023-2030


The Bronchodilators Market is projected to reach USD 27.59 billion by 2030 from USD 17.49 billion in 2022, at a CAGR of 5.85% during the forecast period.

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Bronchodilators Market.
  • Based on Drug Class, market is studied across Anticholinergic Bronchodilators, Beta-Adrenergic Bronchodilators, and Xanthine Derivative. The Beta-Adrenergic Bronchodilators is projected to witness significant market share during forecast period.
  • Based on Route of Administration, market is studied across Injectable, Nasal, and Oral. The Oral is projected to witness significant market share during forecast period.
  • Based on Disease, market is studied across Asthma and COPD. The Asthma is projected to witness significant market share during forecast period.
  • Based on End-users, market is studied across Hospitals and Specialty Clinics. The Specialty Clinics is projected to witness significant market share during forecast period.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa is projected to witness significant market share during forecast period.
Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Bronchodilators Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Bronchodilators Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Bronchodilators Market, highlighting leading vendors and their innovative profiles. These include AdvaCare Pharma, AMGIS Lifescience Ltd., AstraZeneca PLC, Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Cipla Limited, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Mylan Inc. by Viatris Inc., Nephron Pharmaceuticals Corporation, Novartis AG, Perrigo Company PLC, Pfizer Inc., Prasco Laboratories, Ralington Pharma LLP, Siemens Healthcare GmbH, Steris Healthcare Pvt. Ltd., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., Vectura Group PLC, and Zydus Group.

The report offers valuable insights on the following aspects:
  1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
  2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
  3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
  4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
  5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
  1. What is the market size and forecast for the Bronchodilators Market?
  2. Which products, segments, applications, and areas hold the highest investment potential in the Bronchodilators Market?
  3. What is the competitive strategic window for identifying opportunities in the Bronchodilators Market?
  4. What are the latest technology trends and regulatory frameworks in the Bronchodilators Market?
  5. What is the market share of the leading vendors in the Bronchodilators Market?
  6. Which modes and strategic moves are suitable for entering the Bronchodilators Market?


Note: PDF & Excel + Online Access - 1 Year

Table of Contents

184 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Bronchodilators Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of respiratory disorders worldwide
5.1.1.2. Growing awareness about asthma and cystic fibrosis respiratory disorders
5.1.2. Restraints
5.1.2.1. Huge expenditure required for treating chronic bronchitis
5.1.3. Opportunities
5.1.3.1. Robust research activities to develop noval bronchodilators
5.1.3.2. Increasing number of clinical trials to treat chronic bronchitis
5.1.4. Challenges
5.1.4.1. Side effects associated with consumption of bronchodilators
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Bronchodilators Market, by Drug Class
6.1. Introduction
6.2. Anticholinergic Bronchodilators
6.3. Beta-Adrenergic Bronchodilators
6.4. Xanthine Derivative
7. Bronchodilators Market, by Route of Administration
7.1. Introduction
7.2. Injectable
7.3. Nasal
7.4. Oral
8. Bronchodilators Market, by Disease
8.1. Introduction
8.2. Asthma
8.3. COPD
9. Bronchodilators Market, by End-users
9.1. Introduction
9.2. Hospitals
9.3. Specialty Clinics
10. Americas Bronchodilators Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Bronchodilators Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Bronchodilators Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. AdvaCare Pharma
14.1.2. AMGIS Lifescience Ltd.
14.1.3. AstraZeneca PLC
14.1.4. Boehringer Ingelheim International GmbH
14.1.5. Cambrex Corporation
14.1.6. Catalent, Inc.
14.1.7. Cipla Limited
14.1.8. GlaxoSmithKline PLC
14.1.9. Glenmark Pharmaceuticals Limited
14.1.10. Hikma Pharmaceuticals PLC
14.1.11. Lupin Limited
14.1.12. Mylan Inc. by Viatris Inc.
14.1.13. Nephron Pharmaceuticals Corporation
14.1.14. Novartis AG
14.1.15. Perrigo Company PLC
14.1.16. Pfizer Inc.
14.1.17. Prasco Laboratories
14.1.18. Ralington Pharma LLP
14.1.19. Siemens Healthcare GmbH
14.1.20. Steris Healthcare Pvt. Ltd.
14.1.21. Sun Pharmaceutical Industries Limited
14.1.22. Teva Pharmaceutical Industries Ltd.
14.1.23. Thermo Fisher Scientific Inc.
14.1.24. Vectura Group PLC
14.1.25. Zydus Group
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us